title: Novel small-molecule therapy of Hodgkin lymphoma.
abstract: The treatment of Hodgkin lymphoma continues to be based on combination chemotherapy and radiation therapy. Although this treatment strategy produces a high cure rate, short- and long-term toxic effects continue to be problematic for young cured patients. In this review we focus on emerging novel therapies using small molecules that target specific survival pathways in the cancer cells. This approach is aimed at improving the cure rate while reducing treatment-related toxicity.
authors.affiliation: Department of Lymphoma/Myeloma, MD Anderson Cancer Center, Houston, TX 77030, USA. dbuglio@mdanderson.org
authors.forename: Daniela
authors.initials: D
authors.lastname: Buglio
authors.forename: Georgios
authors.initials: G
authors.lastname: Georgakis
authors.forename: Anas
authors.initials: A
authors.lastname: Younes
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018841:HSP90 Heat-Shock Proteins / Q000037:antagonists & inhibitors; D056572:Histone Deacetylase Inhibitors; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D020928:Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors; D000081082:Phosphoinositide-3 Kinase Inhibitors; D061988:Proteasome Inhibitors; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000037:antagonists & inhibitors; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents; D018841:HSP90 Heat-Shock Proteins; D056572:Histone Deacetylase Inhibitors; D000081082:Phosphoinositide-3 Kinase Inhibitors; D061988:Proteasome Inhibitors; D019253:Proto-Oncogene Proteins c-bcl-2; D020928:Mitogen-Activated Protein Kinases